Guiding Breast Cancer Treatment | Oncotype DX Test

Portrait of senior woman sitting on porch.

Node-Negative

The Oncotype DX Breast Recurrence Score test is the only17 test validated to predict chemotherapy benefit for your patients with HR+, HER2-, node-negative, early-stage, invasive breast cancer and help guide treatment decisions.1-4

Loading component...

Oncotype DX value in clinical practice for node-negative, early-stage breast cancer patients - TAILORx and NSABP B-20 results show that most patients do not benefit from chemotherapy.

Loading component...

Clinical evidence has demonstrated:

Patients with Recurrence Score^® results 0–25 do not benefit from the addition of chemotherapy to endocrine therapy1-4
Patients with Recurrence Score results 26–100 derive a significant and increasing benefit from the addition of chemotherapy to endocrine therapy3
An exploratory analysis suggests that patients ≤50 years of age with Recurrence Score results 16–25 may benefit from chemotherapy2,4

Loading component...

Loading component...

In TAILORx, an exploratory analysis suggests that the effect of chemotherapy significantly differs across age groups and Recurrence Score results for invasive disease-free survival* and distant recurrence-free interval.**

Loading component...

Oncotype DX value in clinical practice for node-negative, early-stage breast cancer patients -TAILORx analysis - Guiding Treatment based on Recurrence Score Results and Age.

Loading component...

* Invasive disease–free survival defined as the first event of distant recurrence, local–regional recurrence, contralateral breast or other second primary cancer, or death without cancer recurrence.
** Distant recurrence-free interval defined as first event of distant recurrence or death from breast cancer.

Clinical risk features alone (tumour size, grade, clinical risk category) are proven to be prognostic factors, however, insufficient to determine chemotherapy benefit.2

Exploratory analyses were performed to evaluate whether subgroups may derive benefit from the addition of chemotherapy to endocrine therapy in patients with Recurrence Score results 11–25.2

Loading component...

Oncotype DX value in clinical practice for node-negative, early-stage breast cancer patients - Exploratory analyses - No benefit from the addition of chemotherapy to endocrine therapy in patients with Recurrence Score results 11–25.

Loading component...

73% of patients with high clinical risk had Recurrence Score results 0-25 and may have been overtreated if decisions had been made without the Oncotype DX test

Loading component...

Oncotype DX value in clinical practice for node-negative, early-stage breast cancer patients - can help reduce risks of over- and undertreatment in high and low clinical risk patients.

Loading component...

43% of patients with Recurrence Score results 26-100 had low clinical risk and may have been undertreated if decisions had been made without the Oncotype DX test

Loading component...

The Oncotype DX Breast Recurrence Score test is the standard of care to guide adjuvant treatment in HR+, HER2−, early-stage breast cancer, for both node-negative and node-positive patients5-10,17,21

Loading component...

Oncotype DX value in clinical practice for node-negative, early-stage breast cancer patients - standard of care to guide adjuvant treatment in HR+, HER2–, early-stage breast cancer patients.

Loading component...

Since clinical risk features alone are not sufficient to determine CT benefit, the Oncotype DX Breast Recurrence Score test should be used for:2,16

All patients for whom chemotherapy may be spared
All patients for whom chemotherapy may be life-saving

Loading component...

References

Paik et al. J Clin Oncol. 2006.
Sparano et al. NEJM 2018.
Geyer et al. NPJ Breast Cancer. 2018.
Sparano et al. NEJM Evidence 2024.
Barni et al. ESMO. 2018.
Gligorov et al. Oncologist. 2015.
Curtit et al. Breast. 2019.
Barni et al. EBCC. 2018.
Battisti et al. EBCC. 2019.
Petráková et al. St Gallen conference. 2019.
Sparano and Paik. J Clin Oncol. 2008.
Sparano et al. N Engl J Med. 2015.
Blok et al. Cancer Treatment Reviews. 2018.
Albanell et al. Eur J Cancer. 2016.
Hochheiser. J Comp Eff Res. 2019.
Bello et al. Ann Surg Oncc. 2018.
NCCN Guidelines Insights: Breast Cancer, Version 1.2026. https://www.nccn.org/store/login/login.aspx?ReturnURL=https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf
IQWIG Press Release, September 2018.
NICE DG58. https://www.nice.org.uk/guidance/dg58
Curigliano et al. Ann Oncol 2023.
Andre et al. J Clin Oncol 2022.
Loibl et al. Ann Oncol 2024.

National Comprehensive Cancer Network (NCCN) and NCCN are registered trademarks of NCCN. ASCO and ESMO are trademarks of the American Society of Clinical Oncology and European Society for Medical Oncology.
NCCN, National Institute for Health and Care Excellence (NICE), St Gallen International Consensus Panel, ASCO and ESMO do not endorse any product or therapy.
NICE DG34 2018 Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer. Available from HYPERLINK "http://www.nice.org.uk/guidance/dg34"www.nice.org.uk/guidance/dg34. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication

Loading component...

Node-Positive

The Oncotype DX Breast Recurrence Score test is predictive of chemotherapy benefit for your postmenopausal patients with HR+, HER2-, node-positive (1-3 positive nodes), early-stage, invasive breast cancer as demonstrated by SWOG-8814.1 Data from SWOG-8814 and RxPONDER show that a substantial proportion of these patients may be spared chemotherapy.1-3

Loading component...

Oncotype DX value in clinical practice for node-positive, early-stage breast cancer patients - standard of care to guide adjuvant treatment in HR+, HER2–, early-stage breast cancer patients.

Loading component...

The SWOG 8814 study established the Oncotype DX^® test as predictive of CT benefit in node-positive postmenopausal patients.1 Initial results from the RxPONDER study add to the findings of SWOG 8814 by providing a refined estimate of CT benefit in N1 patients with the following results:2,3

N1 postmenopausal patients with Recurrence Score^® results 0-25 may be spared chemotherapy, independent of clinical pathological parameters2,3
N1 premenopausal patients with Recurrence Score results 0-25 derive a 2.4% benefit from chemotherapy in terms of distant recurrence-free interval at 5 years3

Loading component...

A large proportion4,5 of HR+, HER2-, node-positive postmenopausal patients receive chemotherapy as node-positive disease is considered high clinical risk due to worse prognosis.6 Average chemotherapy treatment rates without genomic testing are in the range of 70% for this patient population.4,5 RxPONDER demonstrated that many of these patients may be overtreated, assuming that chemotherapy was considered because of their high clinical risk,2,3 and the Oncotype DX test can help make informed treatment decisions.

Loading component...

Loading component...

Another recent study published in 2023 shows that the Oncotype DX^® test increases confidence and concordance among oncologists in adjuvant chemotherapy recommendations for early-stage breast cancer.7

The study concludes that:

the Oncotype DX test significantly reduces uncertainty related to therapeutic decisions
the Oncotype DX test reduces discordance in treatment choice among oncologists

Loading component...

Loading component...

In summary, adjuvant chemotherapy may be guided with the Oncotype DX test to identify a significant proportion of node-positive patients (with up to 3 positive nodes) who may not benefit from the addition of chemotherapy.1-3

The Oncotype DX Breast Recurrence Score^® test should be used for early stage, HR+, HER2- patients with up to 3 nodes involved:

All patients for whom chemotherapy may be spared1-3
All patients for whom chemotherapy may be life-saving1-3

Loading component...

References

Albain et al. Lancet Oncol. 2010.
Kalinsky et al. NEJM. 2021.
Kalinsky et al. SABCS. 2021. GS2-07.
Allemani et al. Int J Cancer. 2013.
Zhang et al. Breast Can Res Treat. 2020.
Tonellotto et al. Eur J Breast Health. 2019.
Licata L, et al. NPJ Breast Cancer. 2023.

Loading component...

Have questions about Oncotype DX^®?

Doctor sitting with patient having a discussion.

Value in clinical practice

The Oncotype DX Breast Recurrence Score® test provides significant value in clinical practice

For node-negative, early-stage breast cancer patients

Loading component...

Loading component...

How does the Oncotype DX® test help guide treatment decisions?

Loading component...

Loading component...

Guiding treatment based on Recurrence Score results and age

Loading component...

Loading component...

How can the Oncotype DX test help reduce the risk of over- and undertreatment?

Loading component...

Loading component...

Loading component...

High clinical risk patients

Loading component...

Loading component...

Low clinical risk patients

Loading component...

Loading component...

Loading component...

Loading component...

Loading component...

Loading component...

References

Loading component...

For node-positive, early-stage breast cancer patients

Loading component...

Loading component...

How does the Oncotype DX test help guide treatment decisions?

Loading component...

Loading component...

Use of the Oncotype DX test may reduce the risk of overtreatment with chemotherapy1-3

Loading component...

Loading component...

Loading component...

Loading component...

Clinical utility of the Oncotype DX test

Loading component...

References

Loading component...

Loading component...

Loading component...

Loading component...

For node-negative, early-stage breast cancer patients

How does the Oncotype DX® test help guide treatment decisions?

Guiding treatment based on Recurrence Score results and age

How can the Oncotype DX test help reduce the risk of over- and undertreatment?

High clinical risk patients

Low clinical risk patients

References

For node-positive, early-stage breast cancer patients

How does the Oncotype DX test help guide treatment decisions?

Use of the Oncotype DX test may reduce the risk of overtreatment with chemotherapy1-3

Clinical utility of the Oncotype DX test

References

The Oncotype DX Breast Recurrence Score^® test provides significant value in clinical practice

How does the Oncotype DX^® test help guide treatment decisions?

How does the Oncotype DX^® test help guide treatment decisions?